Qiagen Touts SABiosciences' Bioinformatics Prowess as Key to Biomarker Discovery

A company spokesperson said that SABiosciences, which Qiagen acquired last year, has developed tools that can identify specific biomarkers to help clinicians make better treatment decisions for their patients, focus their medical research into diseases like cancer, and help drug companies target potential candidates for clinical trials.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.